Fig. 1

Effects of phytogalactolipid-enriched fraction CRA on tumor inhibition and B cell infiltration. Panel A. The inhibitory effects of CRA on tumor growth. Panel B. CRA inhibited tumor volumes in a dose-dependent manner at day 33. CT26.CL25 tumor-bearing mice were orally administrated with 25, 50, or 100 mg/kg of CRA every day. Tumor volumes were recorded every 3 days (n = 10). **: P < 0.01; ***: P < 0.001, compared to the control group. ns: no significant difference. Panel C. CRA did not affect the body weight in CRC tumor-bearing mice. After CRA treatment, Panel D. the proportion of splenic CD19⁺ B cells, Panel E. CD19⁺CD86⁺ B cells, and Panel F. different B cell subsets in splenocytes were determined (n = 10). Panel G. The expression of TIL-B cells (B220, red) in the tumor by IHC staining (magnification, 400 ×). Panel H. The proportion of TIL-CD19⁺ B cells, Panel I. TIL-CD19⁺CD86.⁺ B cells, and Panel J. Different TIL-B cell subsets were determined (n = 5)